Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 7, 2013

View Archived Issues

Ono Pharmaceutical advances key programs in first quarter of fiscal 2013

BMS-241027 well tolerated in healthy female subjects

BeiGene and GENEWIZ form collaboration for cancer biomarker discovery

Identification and validation of a naturally occurring anti-anthrax antibiotic

Galectin reports encouraging preclinical IPF model data

Monoclonal antibody interferes with inactivation of coagulation factor VIII

Mitsubishi Tanabe Pharma reports progress of first quarter of fiscal 2013

Bayer profiles novel PR modulator for the treatment of uterine fibrosis

Addex Therapeutics synthesizes new metabotropic glutamate receptor modulators

arGEN-X licenses NHance antibody half-life extension technology

Eli Lilly reports novel LTB4 receptor antagonist

Agios Pharmaceuticals prepares novel IDH inhibitors for cancer

Ensemble Therapeutics forms strategic collaboration for macrocyclic IL-17 antagonists

New sodium channel blockers designed by Vertex Pharmaceuticals

Antisense Therapeutics provides update on phase II ATL-1103 trial

MultiCell Technologies and Genisphere assess targeted delivery of MCT-485

Novel MetAP 2 inhibitors divulged by Zafgen

Companies seek new formulation approval for limaprost alfadex in Japan

Ultragenyx commences development program in GLUT-1 deficiency syndrome

Pluristem Therapeutics receives grant from Israeli government

Regeneron and Bayer planning U.S. and E.U. submissions for Eylea in DME this year

FDA committee votes against approval of Otsuka's tolvaptan in ADPKD

StemCells reports 2-year data for HuCNS-SC cells in patients with Pelizaeus-Merzbacher disease

China CDC and Aeras sign R&D agreement for tuberculosis vaccines

Valeant Pharmaceuticals acquires Bausch + Lomb

Actavis acquires worldwide rights for oral antifungal agent from Palau Pharma

FDA committee recommends approval of Bayer's riociguat for two pulmonary hypertension indications

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.